# US 2021/0231692 A1 · Method for obtaining information on cognitive function, method for determining effectiveness of medical intervention about cognitive function

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0231692 A1
- Document ID: US20210231692A1
- Status: Published application
- Kind: A1
- Application number: 17/154,132
- Filed: 2021-01-21
- Published: 2021-07-29
- Earliest claimed: 2020-01-24
- Assignees: Sysmex Corporation
- Applicants: Sysmex Corporation
- Inventors: Amane HARADA; Katsuhiro MURAKAMI; Keiko MIWA; Elnaz NAKHAEI
- Web page: https://patentgrep.com/patent/US20210231692A1

## CPC

- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor
- G01N 33/58: involving labelled substances (G01N33/53 takes precedence)
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- G16H 10/40: for data related to laboratory analysis, e.g. patient specimen analysis
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G01N 33/543: with an insoluble carrier for immobilising immunochemicals
- G01N 2333/775: Apolipopeptides
- G01N 2458/00: Labels used in chemical analysis of biological material
- G01N 2800/2821: Alzheimer
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Disclosed is a method for obtaining information about cognitive function of a subject, comprising contacting lipoprotein in a blood sample of a subject with a labeled lipid and measuring the labeled lipid incorporated into the lipoprotein, wherein the obtained measured value is an indicator of cognitive impairment.

## Claims

### Claim 1

A method for obtaining information on cognitive function of a subject, comprising: contacting lipoprotein in a blood sample of a subject with a labeled lipid;
and measuring the labeled lipid incorporated into the lipoprotein to obtain a measured value, wherein the measured value is an indicator of cognitive impairment.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the information on cognitive function is information on risk of cognitive function decline of the subject and/or information indicating a state of cognitive function of the subject.

### Claim 3 (depends on 2)

The method according to claim 2, wherein, when the measured value is equal to or less than a predetermined threshold, the measured value suggests that a risk of declining the cognitive function of the subject is high and/or that the cognitive function of the subject is declined.

### Claim 4 (depends on 2)

The method according to claim 2, wherein, when the measured value is greater than a predetermined threshold, the measured value suggests that a risk of declining the cognitive function of the subject is low and/or that the cognitive function of the subject is not declined.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the information on cognitive function is information on onset risk of a central nervous system disease and/or information indicating a presence or absence of a central nervous system disease.

### Claim 6 (depends on 5)

The method according to claim 5, wherein, when the measured value is equal to or less than a predetermined threshold, the measured value suggests that the risk of developing a central nervous system disease is high and/or that the subject develops a central nervous system disease.

### Claim 7 (depends on 5)

The method according to claim 5, wherein, when the measured value is greater than a predetermined threshold, the measured value suggests that the risk of developing a central nervous system disease is low and/or that the subject does not develop a central nervous system disease.

### Claim 8 (depends on 5)

The method according to claim 5, wherein the central nervous system disease is Alzheimer's disease.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the labeled lipid is a labeled sterol.

### Claim 10 (depends on 9)

The method according to claim 9, wherein
the labeled sterol is tagged cholesterol represented by a following formula (I):
wherein R1 is an alkylene group having 1 to 6 carbon atoms which optionally have a methyl group;
X and Y are identical or different, and are represented by —R2—NH—, —NH—R2—, —R2—(C═O)—NH—, —(C═O)—NH—R2—, —R2—NH—(C═O)—, —NH—(C═O)—R2—, —R2—(C═O)—, —(C═O)—R2—, —R2—(C═O)—O—, —(C═O)—O—R2—, —R2—O—(C═O)—, —O—(C═O)—R2—, —R2—(C═S)—NH—, —(C═S)—NH—R2—, —R2—NH—(C═S)—, —NH—(C═S)—R2—, —R2—O—, —O—R2—, —R2—S—, or —S—R2—, and each R2 is independently an atomic bonding, an alkylene group having 1 to 10 carbon atoms which optionally have a substituent, or an arylene group or heteroarylene group having 6 to 12 carbon atoms which optionally have a substituent, or a cycloalkylene group or heterocycloalkylene group having 3 to 8 carbon atoms which optionally have a substituent;
L is represented by —(CH2)d—[R3—(CH2)f]f— or —[(CH2)f—R3]f—(CH2)d—, and R3 is an oxygen atom, a sulfur atom, —NH—, —NH—(C═O)— or —(C═O)—NH—;
TAG is a tag;
a and c are identical or different and are an integer of 0 to 6,
b is 0 or 1;
d and e are identical or different and are an integer of 0 to 12; and
f is an integer of 0 to 24.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the measurement comprises: contacting the lipoprotein incorporating the labeled lipid with a capture body that binds to the lipoprotein to form a complex, wherein the complex comprises the lipoprotein incorporating the labeled lipid and the capture body.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the capture body is an antibody that specifically binds to the lipoprotein.

### Claim 13 (depends on 1)

The method according to claim 1, further comprising:
determining that a risk of declining the cognitive function of the subject is high and/or that the cognitive function of the subject is declined when the measured value is equal to or less than a predetermined threshold, and
performing medical intervention about cognitive function on the subject when it is determined that the risk of declining the cognitive function of the subject is high and/or that the cognitive function of the subject is declined.

### Claim 14

A method for determining effectiveness of medical intervention about cognitive function, comprising:
first contacting lipoprotein in a blood sample of a subject with a labeled lipid and measuring the labeled lipid incorporated into the lipoprotein to obtain a first measured value;
after the first contacting, performing the medical intervention about cognitive function on the subject;
after the performing, second contacting lipoprotein in a blood sample of the subject with a labeled lipid and measuring the labeled lipid incorporated into the lipoprotein to obtain a second measured value; and
comparing the first measured value with the second measured value to determine effectiveness of the medical intervention.

### Claim 15 (depends on 14)

The method according to claim 14, wherein, when the second measured value is greater than the first measured value, it is determined that the medical intervention is effective for the subject.

### Claim 16 (depends on 15)

The method according to claim 15, further comprising second performing the medical intervention about cognitive function on the subject when it is determined that the medical intervention is effective for the subject.

### Claim 17 (depends on 14)

The method according to claim 14, wherein, when the second measured value is equal to or less than the first measured value, it is determined that the medical intervention is not effective for the subject.

### Claim 18 (depends on 14)

The method according to claim 14, wherein the first contacting comprises: contacting the lipoprotein incorporating the labeled lipid with a capture body that binds to the lipoprotein to form a complex, wherein the complex comprises the lipoprotein incorporating the labeled lipid and the capture body.

### Claim 19 (depends on 14)

The method according to claim 14, wherein the second contacting comprises: contacting the lipoprotein incorporating the labeled lipid with a capture body that binds to the lipoprotein to form a complex, wherein the complex comprises the lipoprotein incorporating the labeled lipid and the capture body.

### Claim 20 (depends on 14)

The method according to claim 14, wherein the medical intervention comprises administering to the subject an agent selected from the group consisting of donepezil, memantine, galantamine and rivastigmine.
